SI3429591T1 - Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe - Google Patents
Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabeInfo
- Publication number
- SI3429591T1 SI3429591T1 SI201731362T SI201731362T SI3429591T1 SI 3429591 T1 SI3429591 T1 SI 3429591T1 SI 201731362 T SI201731362 T SI 201731362T SI 201731362 T SI201731362 T SI 201731362T SI 3429591 T1 SI3429591 T1 SI 3429591T1
- Authority
- SI
- Slovenia
- Prior art keywords
- menin
- mll
- inhibitors
- methods
- pyrimidine derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309372P | 2016-03-16 | 2016-03-16 | |
| US201662334369P | 2016-05-10 | 2016-05-10 | |
| US201662431389P | 2016-12-07 | 2016-12-07 | |
| US201762446640P | 2017-01-16 | 2017-01-16 | |
| EP17767462.9A EP3429591B1 (en) | 2016-03-16 | 2017-03-15 | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| PCT/US2017/022564 WO2017161028A1 (en) | 2016-03-16 | 2017-03-15 | Substituted inhibitors of menin-mll and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3429591T1 true SI3429591T1 (sl) | 2023-07-31 |
Family
ID=59851028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201731362T SI3429591T1 (sl) | 2016-03-16 | 2017-03-15 | Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10781218B2 (sl) |
| EP (2) | EP3429591B1 (sl) |
| JP (3) | JP6919977B2 (sl) |
| KR (1) | KR102419531B1 (sl) |
| CN (2) | CN109152784B (sl) |
| AU (1) | AU2017232516B2 (sl) |
| BR (1) | BR112018068703B1 (sl) |
| CA (1) | CA3015847A1 (sl) |
| CY (1) | CY1126066T1 (sl) |
| DK (1) | DK3429591T3 (sl) |
| ES (1) | ES2947636T3 (sl) |
| FI (1) | FI3429591T3 (sl) |
| HK (1) | HK1259232A1 (sl) |
| HR (1) | HRP20230537T1 (sl) |
| HU (1) | HUE061989T2 (sl) |
| IL (1) | IL261606B (sl) |
| LT (1) | LT3429591T (sl) |
| MD (1) | MD3429591T2 (sl) |
| MX (1) | MX2018011105A (sl) |
| PH (1) | PH12018501952A1 (sl) |
| PL (1) | PL3429591T3 (sl) |
| PT (1) | PT3429591T (sl) |
| RS (1) | RS64261B1 (sl) |
| SG (1) | SG11201807982UA (sl) |
| SI (1) | SI3429591T1 (sl) |
| TW (1) | TWI747889B (sl) |
| WO (1) | WO2017161028A1 (sl) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160083343A1 (en) | 2013-03-15 | 2016-03-24 | Global Blood Therapeutics, Inc | Compounds and uses thereof for the modulation of hemoglobin |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| EP3302057A4 (en) | 2015-06-04 | 2018-11-21 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| KR20180098679A (ko) | 2016-01-22 | 2018-09-04 | 잔센파마슈티카엔.브이. | Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체 |
| HUE047684T2 (hu) | 2016-01-22 | 2020-05-28 | Janssen Pharmaceutica Nv | Új szubsztituált cianoindolin származékok mint NIK inhibitorok |
| TWI743096B (zh) | 2016-03-16 | 2021-10-21 | 美商庫拉腫瘤技術股份有限公司 | Menin-mll之橋聯雙環抑制劑及使用方法 |
| HUE061989T2 (hu) | 2016-03-16 | 2023-09-28 | Kura Oncology Inc | Szubsztituált tieno[2,3-D]pirimidin származékok mint menin-MLL inhibitorai és alkalmazási eljárások |
| MX2018013433A (es) | 2016-05-02 | 2019-07-18 | Univ Michigan Regents | Piperidinas como inhibidores de menina. |
| EP3478675B1 (en) | 2016-06-30 | 2020-04-22 | Janssen Pharmaceutica NV | Heteroaromatic derivatives as nik inhibitors |
| AU2017289317B2 (en) | 2016-06-30 | 2021-04-01 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as NIK inhibitors |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| MX2019002797A (es) | 2016-09-09 | 2019-05-09 | Novartis Ag | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje. |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| BR112019004691A2 (pt) | 2016-09-14 | 2019-06-25 | Janssen Pharmaceutica Nv | inibidores bicíclicos em espiro da interação menina-mll |
| EP3538101A4 (en) | 2016-11-14 | 2020-08-05 | Virginia Commonwealth University | CANCER INVASION, UTILIZATION AND / OR METASTASIS INHIBITORS |
| CN110248946B (zh) | 2016-12-15 | 2023-05-23 | 詹森药业有限公司 | Menin-MLL相互作用的氮杂环庚烷抑制剂 |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| US11944627B2 (en) * | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| EP3600313A4 (en) | 2017-03-31 | 2020-09-23 | The Regents of The University of Michigan | PIPERIDINES AS COVALENT MENINE INHIBITORS |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| CN110869021B (zh) | 2017-07-10 | 2023-06-30 | 细胞基因公司 | 抗增殖化合物及其使用方法 |
| EP3651752A1 (en) | 2017-07-11 | 2020-05-20 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| EP3684361A4 (en) | 2017-09-20 | 2021-09-08 | Kura Oncology, Inc. | MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE |
| EA202090871A1 (ru) | 2017-10-06 | 2020-07-03 | Форма Терапьютикс, Инк. | Ингибирование убиквитин-специфической пептидазы 30 |
| HUE062460T2 (hu) | 2017-10-27 | 2023-11-28 | Boehringer Ingelheim Int | TRPC6 inhibitorok |
| TW201927777A (zh) * | 2017-12-19 | 2019-07-16 | 大陸商基石藥業（蘇州）有限公司 | Ido抑制劑 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| CA3092470A1 (en) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| CN110204552B (zh) * | 2018-02-28 | 2021-08-17 | 中国科学院上海药物研究所 | 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途 |
| US11261192B2 (en) | 2018-03-09 | 2022-03-01 | Recurium Ip Holdings, Llc | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones |
| CA3093802A1 (en) | 2018-03-13 | 2019-09-19 | Shire Human Genetic Therapies, Inc. | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
| US11325921B2 (en) | 2018-03-30 | 2022-05-10 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active crosslinked cyclic secondary amine derivative |
| WO2019200267A1 (en) | 2018-04-12 | 2019-10-17 | Terns, Inc. | Tricyclic ask1 inhibitors |
| AR114803A1 (es) | 2018-04-23 | 2020-10-14 | Celgene Corp | Compuestos de 4-aminoisoindolin-1,3-diona sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos |
| JP7391046B2 (ja) | 2018-05-18 | 2023-12-04 | インサイト・コーポレイション | Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体 |
| CR20240054A (es) | 2018-07-05 | 2024-02-26 | Incyte Corp | DERIVADOS DE PIRAZINA FUSIONADOS COMO INHIBIDORES DE A2A/A2B (Div. 2021-71) |
| EP3853233A1 (en) | 2018-09-18 | 2021-07-28 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
| JP2022503792A (ja) * | 2018-09-26 | 2022-01-12 | クラ オンコロジー，インク． | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| AU2019356011A1 (en) | 2018-10-05 | 2021-04-01 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| MX2021006034A (es) | 2018-11-22 | 2021-09-21 | Qilu Regor Therapeutics Inc | Agonistas de glp-ir y usos de los mismos. |
| BR112021007421A2 (pt) | 2018-12-06 | 2021-08-03 | Daiichi Sankyo Company, Limited | derivado de cicloalcano-1,3-diamina |
| EP3906029A4 (en) | 2018-12-31 | 2022-09-21 | Biomea Fusion, LLC | INHIBITORS OF MENIN-MLL INTERACTION |
| MA54758A (fr) | 2019-01-18 | 2022-04-27 | Astrazeneca Ab | Inhibiteurs de pcsk9 et leurs procédés d'utilisation |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶 |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| CA3145864A1 (en) | 2019-07-03 | 2021-01-07 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
| PE20221010A1 (es) | 2019-08-14 | 2022-06-15 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 |
| EP4031245A1 (en) | 2019-09-18 | 2022-07-27 | Takeda Pharmaceutical Company Limited | Heteroaryl plasma kallikrein inhibitors |
| US11787796B2 (en) | 2019-09-18 | 2023-10-17 | Takeda Pharmaceutical Company Limited | Plasma Kallikrein inhibitors and uses thereof |
| JP2022551668A (ja) | 2019-10-11 | 2022-12-12 | インサイト・コーポレイション | Ｃｄｋ２阻害剤としての二環式アミン |
| PE20221040A1 (es) | 2019-10-25 | 2022-06-17 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| KR20220124176A (ko) | 2019-12-06 | 2022-09-13 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 치환된 테트라하이드로푸란 |
| AR121044A1 (es) | 2019-12-23 | 2022-04-13 | Blueprint Medicines Corp | Inhibidores de egfr |
| JP2023509452A (ja) | 2020-01-03 | 2023-03-08 | バーグ エルエルシー | がんを処置するためのｕｂｅ２ｋモジュレータとしての多環式アミド |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| WO2021231892A1 (en) | 2020-05-15 | 2021-11-18 | Algen Biotechnologies, Inc. | Certain chemical compositions and methods of use thereof |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| WO2022175752A1 (en) | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| CA3216162A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| IL306110A (en) | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxybenzimidazole GLP-1R modulatory compounds |
| BR112023023154A2 (pt) | 2021-05-08 | 2024-01-23 | Janssen Pharmaceutica Nv | Derivados espiro substituídos |
| EP4334320A1 (en) | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Substituted spiro derivatives |
| EP4347588A1 (en) | 2021-06-01 | 2024-04-10 | JANSSEN Pharmaceutica NV | Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives |
| WO2022253289A1 (en) | 2021-06-03 | 2022-12-08 | Janssen Pharmaceutica Nv | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
| WO2022253309A1 (zh) * | 2021-06-03 | 2022-12-08 | 首药控股(北京)股份有限公司 | 取代的杂环化合物及其应用 |
| CA3221259A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| WO2022262796A1 (en) | 2021-06-17 | 2022-12-22 | Janssen Pharmaceutica Nv | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
| CN115515958B (zh) * | 2021-08-04 | 2023-09-29 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
| WO2023011446A1 (zh) * | 2021-08-04 | 2023-02-09 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
| WO2023150635A1 (en) * | 2022-02-04 | 2023-08-10 | Kura Oncology, Inc. | Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5863A (en) | 1848-10-17 | Matthias p | ||
| US949A (en) | 1838-09-27 | Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton | ||
| US510A (en) | 1837-12-07 | soeel | ||
| US5861A (en) | 1848-10-17 | Locking umbrella and parasol | ||
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DE4239169A1 (de) | 1992-11-21 | 1994-05-26 | Merck Patent Gmbh | Cyclobutan - Benzol - Derivate |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| WO1996033172A1 (en) | 1995-04-20 | 1996-10-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors |
| EP0780386B1 (en) | 1995-12-20 | 2002-10-02 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors |
| JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
| EA199900036A1 (ru) | 1996-07-18 | 1999-06-24 | Пфайзер Инк | Ингибиторы металлопротеаз матрикса на основе фосфинатов, фармацевтическая композиция, способ лечения |
| US6153609A (en) | 1996-08-23 | 2000-11-28 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| US5866562A (en) | 1996-10-25 | 1999-02-02 | Bayer Aktiengesellschaft | Ring-bridged bis-quinolines |
| PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
| TR199901849T2 (xx) | 1997-02-03 | 2000-02-21 | Pfizer Products Inc. | Arils�lfonilamino hidroksamik asit t�revleri. |
| WO1998034915A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| PL334997A1 (en) | 1997-02-11 | 2000-03-27 | Pfizer | Derivatives or arylosulphonyl-hydroxamic acid |
| JPH10330377A (ja) | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| US6479487B1 (en) | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| US20070208087A1 (en) | 2001-11-02 | 2007-09-06 | Sanders Virginia J | Compounds, compositions and methods for the treatment of inflammatory diseases |
| EP2048142A3 (en) | 2001-04-26 | 2009-04-22 | Eisai R&D Management Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| EP1401840A4 (en) | 2001-04-30 | 2007-05-16 | Bayer Corp | NEW 4-AMINO-5,6-SUBSTITUTED THIOPHENO 2,3 D | PYRIMIDINE |
| US7115741B2 (en) | 2001-09-06 | 2006-10-03 | Levy Daniel E | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds |
| AU2003255482A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
| AU2003258662A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
| US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| CN1777612A (zh) | 2003-03-31 | 2006-05-24 | 普雷迪克医药品控股公司 | 新的哌啶基氨基－噻吩并[2,3－d]嘧啶化合物 |
| CA2535265C (en) | 2003-08-22 | 2014-01-28 | Dendreon Corporation | Compositions and methods for the treatment of disease associated with trp-p8 expression |
| US20050123906A1 (en) | 2003-11-06 | 2005-06-09 | Rana Tariq M. | Protein modulation |
| CA2573103A1 (en) | 2004-07-06 | 2006-02-09 | Angion Biomedica Corporation | Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
| US7553964B2 (en) | 2005-06-03 | 2009-06-30 | Abbott Laboratories | Cyclobutyl amine derivatives |
| US20060281771A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
| US20060281769A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
| EP1937272A2 (en) | 2005-09-02 | 2008-07-02 | Tibotec Pharmaceuticals Ltd. | Benzodiazepines as hcv inhibitors |
| US7744968B2 (en) | 2005-09-19 | 2010-06-29 | Merck Patent Gmbh | Cyclobutane and spiro[3.3]heptane compounds |
| FR2891829A1 (fr) | 2005-10-12 | 2007-04-13 | Sanofi Aventis Sa | Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique |
| AR057579A1 (es) | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
| US7910595B2 (en) | 2005-12-21 | 2011-03-22 | Abbott Laboratories | Anti-viral compounds |
| US8633201B2 (en) | 2006-04-07 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| WO2008070303A2 (en) | 2006-10-19 | 2008-06-12 | The University Of Chicago | Therapeutics to inhibit mll-menin interaction for treating leukemia |
| EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
| WO2008099019A1 (en) | 2007-02-16 | 2008-08-21 | Tibotec Pharmaceuticals Ltd. | 6-hydroxy-dibenzodiazepinones useful as hepatitis c virus inhibitors |
| FR2913017A1 (fr) | 2007-02-23 | 2008-08-29 | Cerep Sa | Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire |
| DE602008004649D1 (de) | 2007-03-19 | 2011-03-03 | Council Scient Ind Res | Anthranilsäure-derivat als antikrebswirkstoff und verfahren zur herstellung davon |
| WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
| CA2687187A1 (en) | 2007-05-25 | 2008-12-18 | Burnham Institute For Medical Research | Inhibitors of thapsigargin-induced cell death |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| WO2009064388A2 (en) | 2007-11-09 | 2009-05-22 | Liu Jun O | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders |
| JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| KR20110018380A (ko) | 2008-05-22 | 2011-02-23 | 알러간, 인코포레이티드 | Ｃｘｃｒ4 수용체에서 활성을 갖는 이환식 화합물 |
| DE102008027574A1 (de) * | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| MX2011002060A (es) | 2008-08-25 | 2011-04-05 | Irm Llc | Moduladores de la senda de hedgehog. |
| US20100063047A1 (en) | 2008-09-10 | 2010-03-11 | Kalypsys, Inc. | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
| GB0904285D0 (en) * | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| TW201038572A (en) | 2009-03-25 | 2010-11-01 | Gruenenthal Gmbh | Substituted spiro-amide compounds |
| BRPI1010649A2 (pt) | 2009-06-08 | 2016-06-07 | Gruenenthal Gmbh | benzimidazóis, benzotiazóis e benzoxazoles substituídos. |
| WO2010147234A1 (en) | 2009-06-18 | 2010-12-23 | Banyu Pharmaceutical Co.,Ltd. | Diarylamide-spirodiamine derivative |
| WO2011003418A1 (en) | 2009-07-08 | 2011-01-13 | Leo Pharma A/S | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
| SG177628A1 (en) | 2009-07-30 | 2012-03-29 | Univ Singapore | Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity |
| EP2473054B1 (en) * | 2009-09-04 | 2017-06-14 | The Regents of the University of Michigan | Compositions and methods for treatment of leukemia |
| MX2012009475A (es) | 2010-02-22 | 2012-09-12 | Merck Patent Gmbh | Hetarilaminonaftiridinas. |
| CA2808543C (en) | 2010-08-20 | 2016-01-26 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| WO2013019966A1 (en) | 2011-08-04 | 2013-02-07 | Allergan, Inc. | Aromatic bycyclic derivatives as cxcr4 receptor modulators |
| GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| AR090037A1 (es) * | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
| CN103833759A (zh) | 2012-11-23 | 2014-06-04 | 华东理工大学 | 作为blk、flt3抑制剂的蝶啶酮衍生物及其应用 |
| GB201217704D0 (en) | 2012-10-03 | 2012-11-14 | Ucb Pharma Sa | Therapeutic agents |
| WO2014160478A1 (en) | 2013-03-13 | 2014-10-02 | Flatley Discovery Lab | Compounds and methods for the treatment of cystic fibrosis |
| US9216993B2 (en) * | 2013-03-13 | 2015-12-22 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US9212180B2 (en) | 2013-06-12 | 2015-12-15 | The Regents Of The University Of Michigan | Menin-MLL inhibitors and methods of use thereof |
| US9650379B2 (en) | 2013-12-12 | 2017-05-16 | Chong Kun Dang Pharmaceutical Corp. | Azaindole derivatives as selective histone deacetylase (HDAC) inhibitors and pharmaceutical compositions comprising the same |
| LT3126352T (lt) | 2014-04-04 | 2019-01-10 | Syros Pharmaceuticals, Inc. | Nuo ciklino priklausomos kinazės 7 (cdk7) inhibitoriai |
| US20170119769A1 (en) | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| EP3302057A4 (en) | 2015-06-04 | 2018-11-21 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| EP3316969B1 (en) | 2015-07-02 | 2022-03-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| BR112018012707A2 (pt) | 2015-12-22 | 2019-01-29 | Vitae Pharmaceuticals Inc | inibidores da interação de menin-mll |
| UY37073A (es) | 2016-01-13 | 2017-07-31 | Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen |
| EP3407884A4 (en) | 2016-01-26 | 2019-09-11 | Memorial Sloan-Kettering Cancer Center | TARGETING OF CHROMATIN REGULATORS FOR THE INHIBITION OF LEUKEMOGENIC GENE EXPRESSION INNPM1 |
| HUE061989T2 (hu) | 2016-03-16 | 2023-09-28 | Kura Oncology Inc | Szubsztituált tieno[2,3-D]pirimidin származékok mint menin-MLL inhibitorai és alkalmazási eljárások |
| TWI743096B (zh) | 2016-03-16 | 2021-10-21 | 美商庫拉腫瘤技術股份有限公司 | Menin-mll之橋聯雙環抑制劑及使用方法 |
| MX2018013433A (es) | 2016-05-02 | 2019-07-18 | Univ Michigan Regents | Piperidinas como inhibidores de menina. |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| CA3024180A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| WO2018050686A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| AU2017326006B2 (en) | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| EP3684361A4 (en) | 2017-09-20 | 2021-09-08 | Kura Oncology, Inc. | MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE |
-
2017
- 2017-03-15 HU HUE17767462A patent/HUE061989T2/hu unknown
- 2017-03-15 WO PCT/US2017/022564 patent/WO2017161028A1/en active Application Filing
- 2017-03-15 FI FIEP17767462.9T patent/FI3429591T3/fi active
- 2017-03-15 SG SG11201807982UA patent/SG11201807982UA/en unknown
- 2017-03-15 SI SI201731362T patent/SI3429591T1/sl unknown
- 2017-03-15 LT LTEPPCT/US2017/022564T patent/LT3429591T/lt unknown
- 2017-03-15 US US16/082,649 patent/US10781218B2/en active Active
- 2017-03-15 CA CA3015847A patent/CA3015847A1/en active Pending
- 2017-03-15 CN CN201780030597.6A patent/CN109152784B/zh active Active
- 2017-03-15 PT PT177674629T patent/PT3429591T/pt unknown
- 2017-03-15 MX MX2018011105A patent/MX2018011105A/es unknown
- 2017-03-15 AU AU2017232516A patent/AU2017232516B2/en active Active
- 2017-03-15 DK DK17767462.9T patent/DK3429591T3/da active
- 2017-03-15 TW TW106108622A patent/TWI747889B/zh active
- 2017-03-15 HR HRP20230537TT patent/HRP20230537T1/hr unknown
- 2017-03-15 IL IL261606A patent/IL261606B/en unknown
- 2017-03-15 JP JP2018544324A patent/JP6919977B2/ja active Active
- 2017-03-15 RS RS20230441A patent/RS64261B1/sr unknown
- 2017-03-15 CN CN202210112927.9A patent/CN114539284A/zh active Pending
- 2017-03-15 ES ES17767462T patent/ES2947636T3/es active Active
- 2017-03-15 EP EP17767462.9A patent/EP3429591B1/en active Active
- 2017-03-15 KR KR1020187029385A patent/KR102419531B1/ko active IP Right Grant
- 2017-03-15 MD MDE20190122T patent/MD3429591T2/ro unknown
- 2017-03-15 PL PL17767462.9T patent/PL3429591T3/pl unknown
- 2017-03-15 EP EP23151871.3A patent/EP4219449A3/en active Pending
- 2017-03-15 BR BR112018068703-0A patent/BR112018068703B1/pt active IP Right Grant
-
2018
- 2018-09-11 PH PH12018501952A patent/PH12018501952A1/en unknown
-
2019
- 2019-01-24 HK HK19101290.4A patent/HK1259232A1/zh unknown
-
2020
- 2020-07-30 US US16/944,040 patent/US11673898B2/en active Active
-
2021
- 2021-07-21 JP JP2021120820A patent/JP2021183609A/ja active Pending
-
2023
- 2023-06-14 CY CY20231100277T patent/CY1126066T1/el unknown
- 2023-07-13 JP JP2023115451A patent/JP2023153820A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3429591T1 (sl) | Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe | |
| HUS2200003I1 (hu) | Pirrolo [2,3-D]pirimidin származékok mint a Janus-kinázok (JAK) inhibitorai | |
| SI3379933T1 (sl) | Fungicidni sestavki, ki vsebujejo derivate 2,4-diokso-1,4-dihidrotieno (2,3-d)pirimidina | |
| IL247949A0 (en) | New histories of pyrazolopyrimidines and their use as malt1 inhibitors | |
| SI3237423T1 (sl) | Derivati tieno(2,3-C)pirol-4-ona kot inhibitorji ERK | |
| ZA201808014B (en) | Adenine derivatives as protein kinase inhibitors | |
| LT3196194T (lt) | Pirimidino dariniai, tinkami naudoti kaip selektyvūs jak3 ir (arba) jak1 inhibitoriai | |
| GB201802644D0 (en) | Monocyclic,thieno, pyrido and pyrrolo pyrimidine compounds and methods of use and manufacture of the same | |
| HK1248601A1 (zh) | 作為激酶抑制劑的嘧啶衍生物及其治療應用 | |
| IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors | |
| HUE038944T2 (hu) | Tiokromeno[2,3-c]kinolin-12-on származékok és topoizomeráz inhibitorként való alkalmazásuk |